Product Code: RP-ID-10060077 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10060077
Market Overview:
Global Virus Filtration Market Size and Forecast to 2030
The size of the global virus filtration market in 2021 is estimated to be around USD 3 billion. The increasing prevalence of chronic diseases is one of the main factors contributing to growth. The increasing prevalence of chronic diseases such as cancer, diabetes and autoimmune diseases is expected to drive the demand for biologics. According to data from the International Agency for Research on Cancer, there were approximately 14.1 million new cancer confirmed cases worldwide in 2012, and this number is expected to reach 21.7 million by 2030. As a result, the demand for therapeutic biologics continues to grow, thereby driving demand. Virus filtering products for R&D and manufacturing applications. Compliance with regulatory frameworks for drug development and production, such as current Good Manufacturing Practice (cGMP) standards, is another major factor that is expected to drive market development.
Control measures, such as the monitoring and quality control of raw materials, the verification and implementation of effective virus elimination technologies, and the verification that the final product does not contain contaminating viruses mination. Thus, the demand for these products is very high for manufacturing and R&D practices. CRO is working with biotechnology and biopharmaceutical companies to develop new drugs and therapies, which is also expected to support market growth. Service providers, including Charles River Laboratories International, Inc.; WuXi AppTec; and Lonza Group Ltd. provide virus removal services for pharmaceutical and biopharmaceutical companies. Therefore, the growth of the outsourcing industry is a profitable opportunity that can promote the growth of the virus filtration market.
Compared with chemical drugs, the development of biological agents (such as biopharmaceuticals) is very complicated, expensive and time-consuming. Each biopharmaceutical is unique, and it is difficult to produce the same medicine as the original medicine. Even small deviations in protein structure may cause changes in the efficacy, quality and safety of drugs. Therefore, filtration products, such as chromatography reagents and kits, must be used very carefully to avoid changes in protein structure or protein denaturation, which will have a negative impact on the demand for these products.
PRODUCT INSIGHT:
The consumables segment accounted for the majority of the virus filtering market in 2020. Due to the increase in the use of these products for virus filtering, it is expected that there will be lucrative growth during the forecast period. Increasing attention to the development of vaccines, protein therapies, blood products, cell therapy products, gene therapy products, tissue products and stem cell products is expected to drive demand for consumables, including reagents, kits and membranes. Several leading suppliers, including Merck; Danaher; and Sartorius AG, provide a wide range of virus filtration reagents, kits and other consumables. For example, Merck offers a wide range of resins and fillers, such as Eshmuno A resin, ProSep Ultra Plus resin, ProSep-vA Ultra resin, ProSep-vA Ultra chromatography packing, Eshmuno IEX chromatography resin and Fractogel ion exchange chromatography.
Due to the growing demand for biological therapies for the treatment of chronic diseases, this market segment is expected to show a significant compound annual growth rate during the forecast period. Biotechnology and biopharmaceutical manufacturers, such as F. Hoffmann-La Roche Ltd.; Pfizer; and Amgen, install advanced filtration and chromatography systems for the development and production of biological products.
The service sector is expected to show the highest compound annual growth rate during the study period. This is due to the fact that biotechnology companies are increasingly outsourcing drug development and R&D services from CROs. In addition, CRO is working with biotechnology and biopharmaceutical companies to develop new drugs and therapies, which are expected to support the growth of this segment.
INFORMATION TECHNOLOGY:
In 2018, due to the increased use of these products in the manufacturing and research of biological products and medical devices, filtration is the market segment that generates the most revenue. In addition, it provides several advantages, such as it does not denature the protein in the product or sample, and provides high efficiency and purity in laboratory scale as well as large-scale operations. The filtration part is expected to grow at a profitable rate. During the forecast period, due to the increase in R&D investment of suppliers and the improvement of products.
The company invests heavily in research and development to meet the unmet needs of manufacturers of biopharmaceuticals, biotechnology, and medical devices. For example, Sartorius invested US$60.4 million in the research and development of innovative products in 2016. Advances and new product releases help suppliers maintain market dominance, which is expected to drive the growth of this market segment. For example, in September 2016, Merck KGaA launched a new Viresolve Pro Shield H product for the removal of parvoviruses from therapeutic protein feed streams.
This product is used with Viresolve Pro equipment to increase productivity and efficiency. Due to the advancement of products and the increase in R&D and production of biological agents, the chromatographic market segment is expected to grow at the highest rate. For example, in October 2016, Pall, a subsidiary of Danaher, launched the Cadence BioSMB process system, a new type of chromatography system for the one-time continuous production of biopharmaceuticals.
END USE INFORMATION:
In 2020, biopharmaceutical and biotech companies gained the largest market share due to the growth of R&;D activities, biologics production, and biopharmaceutical industry. For example, according to the Indian Brand Equity Foundation, India’s biopharmaceutical industry is expected to reach US$11.6 billion in 2017 and exceed US$100 billion in 2025. The use rate of virus filtering technology in the United States is very high. Germany, Britain, Japan, China and India. The existence of large biopharmaceutical and biotechnology companies, well-developed healthcare infrastructure, and access to advanced products in these countries are some of the main factors driving growth. Due to the trend of outsourcing R&D and manufacturing to CROs, the CRO sector is expected to experience the highest growth during the forecast period.
The increase in the number of therapeutic protein and vaccine manufacturing companies has led to a growing demand for outsourced services that meet the specific needs of these companies. The medical device business unit is expected to experience a significant compound annual growth rate during the forecast period. Virus removal products are widely used in various medical equipment, including anesthesia systems and ventilators. For example, Humid-Vent HEPA is a mechanical filter for viruses and bacteria, suitable for bacteria/virus filtration and humidification in ventilation and anesthesia systems.
APPLICATION INSIGHT:
In 2020, the biologics division accounted for the largest share of revenue and is expected to grow at the fastest compound annual growth rate during the forecast period. This can be attributed to the increasing prevalence of chronic diseases such as growth hormone deficiency, blood diseases, cancer, diabetes and autoimmune diseases, which have increased the demand for biologics.
According to the World Health Organization (WHO), the global prevalence of diabe
tes among patients over 18 years of age has risen from 8.5% in 2014 to 4.7% in 1980. In addition, the American Cancer Society estimates that 1,762,450 new cancer cases will be diagnosed in 2019. Therefore, more and more advanced virus elimination products are used to develop and produce innovative therapies for the treatment of chronic diseases. Leading biotechnology and biopharmaceutical companies such as F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Merck & Co.; Amgen; Pfizer; and Novo Nordisk A/S continue to work hard to develop new drugs. For example, in May 2016, Eli Lilly launched Taltz (ixekizumab) injection for the treatment of plaque psoriasis (moderate to severe) in the United States. In addition, in October 2016, Merck KGaA was approved by the US FDA for your ZINPLAVA (bezlotoxumab) injection.
The medical device sector is the second largest sector and is expected to grow at a considerable compound annual growth rate during the study period. Some manufacturers are introducing advanced virus removal products. For example, Pall, a subsidiary of Danaher, provides breathing system filters that meet quality standards and ensure high performance for mechanical ventilation in anesthesia and intensive care.
REGIONAL INFORMATION:
North America led the overall market in 2020 and is expected to maintain its dominant position during the forecast period. The mature biotechnology and biopharmaceutical industries in the United States have stimulated the regions demand for advanced virus removal products for R&D and biologics production. Europe is the second largest market due to the high demand for innovative virus filtration products used in the development and production of biological products. In addition, highly developed medical infrastructure and a large amount of R&D investment, mainly concentrated in Germany, the United Kingdom and France, are expected to boost the regional market. Accidents and injuries.
Fast-growing Asian economies such as China, India and Indonesia have untapped growth opportunities that are expected to drive regional growth. The increasing government support for industrialization, the existence of CROs, the availability of low-cost labor, and a relatively loose regulatory environment are attracting medical and biological equipment manufacturers to expand their markets in these regions.
VIRUS FILTRATION INFORMATION MARKET SHARE:
Several major companies operating in the market are Merck KGaA; Sartorius; Danaher; Thermo Fisher Scientific; Charles River Laboratory International; General Electric Medical; Asahi Kasei Medical Co., Ltd.; WuXi AppTec; Lonza Group Co., Ltd.; and Clear Cells. Leading manufacturers provide advanced products through powerful distribution channels around the world. For example, Sartorius has approximately 30 sales offices and 20 manufacturing bases in more than 110 countries around the world. Leading manufacturers gain market share through mergers and acquisitions, strategic cooperation, and new product development.
Mergers and acquisitions help companies expand their existing business and geographic scope. For example, in August 2015, Danaher Corporation completed the acquisition of Pall Corporation, a leading supplier of virus filtration products. Launching new products is another important strategy for companies to consolidate their market position. For example, in October 2016, Pall, a subsidiary of Danaher Corporation, launched the Cadence BioSMB process system for single-use and continuous biopharmaceutical production. The system provides continuous and easy manufacturing program expansion without changing process parameters, adsorbents or buffers.
MARKET SEGMENT COVERED BY THE REPORT:
This report forecasts revenue growth at the global, regional and country levels, and analyzes the latest industry trends in each sub-segment from 2021 to 2030. For the purpose of this research, Kenneth Research has segmented the global virus filtering market report based on products, technologies, applications, end-uses, and regions: Product Outlook (Revenue, USD Million, 2021 to 2030): Consumables Kit And reagents and other instruments filtration system system chromatography-2021 to 2030) Filtration Consumables Instruments Services Chromatography Trumatography Services Insight Services (revenue, millions of dollars, 2021 to 2030) Biological products vaccines and therapies Blood and blood products cells and gene therapy products tissues and tissue products Stem cell products company medical device tissue Contract academic and research laboratories.
Related Reports
Proof of Quality & Reliability
